Header Logo

VICENTE VALERO

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. ASO Visual Abstract: Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol. 2024 Oct 23. PMID: 39443343.
      Citations:    Fields:    
    2. Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol. 2024 Oct 17. PMID: 39419889.
      Citations:    Fields:    
    3. Yam C, Patel M, Hill HA, Sun R, Bassett RL, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT, Yam C, Patel M, Hill HA, Sun R, Bassett RL, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834. PMID: 39356138; PMCID: PMC11520071.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    4. Mitchell MP, Shaitelman SF, Smith BD, Krishnamurthy S, Valero V, Rauch GM, Shen Y, Lin H, Kuerer HM. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. Eur J Surg Oncol. 2024 Aug 22; 50(12):108613. PMID: 39243728.
      Citations:    Fields:    
    5. Moore AM, Caudle AS, Sun SX, Yi M, Smith BD, Valero V, Yang W, Kuerer HM, Hunt KK, Teshome M. Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes at Targeted Axillary Dissection. Ann Surg Oncol. 2024 Oct; 31(11):7264-7270. PMID: 39044106.
      Citations: 1     Fields:    Translation:Humans
    6. Mohamed RM, Panthi B, Adrada BE, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed B, Scoggins ME, Son JB, Thompson A, Tripathy D, Valero V, Wei P, White J, Whitman GJ, Xu Z, Yang W, Yam C, Ma J, Rauch GM. Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Sci Rep. 2024 07 12; 14(1):16073. PMID: 38992094; PMCID: PMC11239818.
      Citations:    Fields:    Translation:Humans
    7. Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595. PMID: 38838676; PMCID: PMC11228653.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Iwase T, Cohen EN, Gao H, Alexander A, Kai M, Chiv V, Wang X, Krishnamurthy S, Liu D, Shen Y, Kida K, Reuben A, Layman RM, Ramirez DL, Tripathy D, Moulder SL, Yam C, Valero V, Lim B, Reuben JM, Ueno NT. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2424-2432. PMID: 38629963; PMCID: PMC11147689.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma J. Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. J Magn Reson Imaging. 2024 Oct; 60(4):1367-1376. PMID: 38294179; PMCID: PMC11289164.
      Citations: 1     Fields:    
    10. Panthi B, Mohamed RM, Adrada BE, Boge M, Candelaria RP, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Pashapoor S, Perez F, Son JB, Sun J, Thompson A, Tripathy D, Valero V, Wei P, White J, Xu Z, Yang W, Zhou Z, Yam C, Rauch GM, Ma J. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol. 2023; 13:1264259. PMID: 37941561; PMCID: PMC10628525.
      Citations:    
    11. Guhan M, Crane SM, Valerius LS, Cruz D, Smith BD, Woodward WA, Mitchell MP, Valero V, Rauch GM, Krishnamurthy S, Warnecke CL, Kuerer HM, Shaitelman SF. Patient Interest in Exploring Nonsurgical Treatment Approaches for Early-Stage Breast Cancer: A Qualitative Study. Int J Radiat Oncol Biol Phys. 2024 Feb 01; 118(2):443-454. PMID: 37802228.
      Citations:    Fields:    Translation:Humans
    12. Xu Z, Rauch DE, Mohamed RM, Pashapoor S, Zhou Z, Panthi B, Son JB, Hwang KP, Musall BC, Adrada BE, Candelaria RP, Leung JWT, Le-Petross HTC, Lane DL, Perez F, White J, Clayborn A, Reed B, Chen H, Sun J, Wei P, Thompson A, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yang W, Yam C, Ma J. Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer. Cancers (Basel). 2023 Oct 02; 15(19). PMID: 37835523; PMCID: PMC10571741.
      Citations:    
    13. Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BK. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. Eur J Breast Health. 2023 Oct; 19(4):267-273. PMID: 37795002; PMCID: PMC10546803.
      Citations:    
    14. Johnson HM, Lin H, Shen Y, Diego EJ, Krishnamurthy S, Yang WT, Smith BD, Valero V, Lucci A, Sun SX, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Rauch GM, Kuerer HM, Exceptional Responders Study Group. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open. 2023 09 05; 6(9):e2333933. PMID: 37707811; PMCID: PMC10502524.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    15. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422. PMID: 37547448; PMCID: PMC10399250.
      Citations:    
    16. Adesoye T, Everidge S, Chen J, Sun SX, Teshome M, Valero V, Woodward WA, Lucci A. Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy. Ann Surg Oncol. 2023 Oct; 30(10):6232-6240. PMID: 37479842.
      Citations:    Fields:    Translation:Humans
    17. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13). PMID: 37444385; PMCID: PMC10339918.
      Citations: 1     
    18. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469. PMID: 37061619.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    19. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401. PMID: 37043123.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    20. Cohen EN, Jayachandran G, Gao H, Peabody P, McBride HB, Alvarez FD, Kai M, Song J, Shen Y, Willey JS, Lim B, Valero V, Ueno NT, Reuben JM. Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients. Cancers (Basel). 2023 Mar 06; 15(5). PMID: 36900406; PMCID: PMC10000974.
      Citations:    
    21. Johnson HM, Valero V, Yang WT, Smith BD, Krishnamurthy S, Shen Y, Lin H, Lucci A, Rauch GM, Kuerer HM. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023 07 01; 237(1):101-108. PMID: 36856291.
      Citations: 2     Fields:    Translation:Humans
    22. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers (Basel). 2023 Feb 06; 15(4). PMID: 36831368; PMCID: PMC9953797.
      Citations: 2     
    23. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep. 2023 01 20; 13(1):1171. PMID: 36670144; PMCID: PMC9859781.
      Citations:    Fields:    Translation:Humans
    24. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Exceptional Responders Clinical Trials Group. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 12; 23(12):1517-1524. PMID: 36306810.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    25. Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell. 2022; 5:876100. PMID: 36034598; PMCID: PMC9403735.
      Citations:    
    26. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889. PMID: 35507014; PMCID: PMC9250637.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    27. Musall BC, Adrada BE, Candelaria RP, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Santiago L, Whitman GJ, Moseley TW, Scoggins ME, Mahmoud HS, White JB, Hwang KP, Elshafeey NA, Boge M, Zhang S, Litton JK, Valero V, Tripathy D, Thompson AM, Yam C, Wei P, Moulder SL, Pagel MD, Yang WT, Ma J, Rauch GM. Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2022 12; 56(6):1901-1909. PMID: 35499264; PMCID: PMC9626398.
      Citations:    Fields:    
    28. Candelaria RP, Adrada BE, Lane DL, Rauch GM, Moulder SL, Thompson AM, Bassett RL, Arribas EM, Le-Petross HT, Leung JWT, Spak DA, Ravenberg EE, White JB, Valero V, Yang WT. Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. Ultrasound Med Biol. 2022 06; 48(6):1010-1018. PMID: 35300879; PMCID: PMC9050953.
      Citations:    Fields:    Translation:Humans
    29. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5). PMID: 35267631; PMCID: PMC8909018.
      Citations:    
    30. Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol. 2022 Apr; 149:110220. PMID: 35193025.
      Citations: 1     Fields:    Translation:HumansCells
    31. Zakon DB, Valero V. What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative review. Chin Clin Oncol. 2021 Dec; 10(6):59. PMID: 35016513.
      Citations:    Fields:    Translation:Humans
    32. Candelaria RP, Spak DA, Rauch GM, Huo L, Bassett RL, Santiago L, Scoggins ME, Guirguis MS, Patel MM, Whitman GJ, Moulder SL, Thompson AM, Ravenberg EE, White JB, Abuhadra NK, Valero V, Litton J, Adrada BE, Yang WT. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol. 2022 01; 29 Suppl 1:S35-S41. PMID: 34272161; PMCID: PMC8755852.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    33. Postlewait LM, Teshome M, Adesoye T, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Sun SX, Woodward WA, Le-Petross HT, Valero V, Ueno NT, Lucci A. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Dec; 28(13):8610-8621. PMID: 34125346.
      Citations: 1     Fields:    Translation:Humans
    34. Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110. PMID: 34120223.
      Citations: 4     Fields:    Translation:Humans
    35. Adrada BE, Candelaria R, Moulder S, Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L, Scoggins ME, Moseley TW, White JB, Ravenberg EE, Yang WT, Rauch GM. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer. 2021 08 15; 127(16):2880-2887. PMID: 33878210; PMCID: PMC8319084.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    36. Chainitikun S, Espinosa Fernandez JR, Long JP, Iwase T, Kida K, Wang X, Saleem S, Lim B, Valero V, Ueno NT. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One. 2021; 16(4):e0250057. PMID: 33861773; PMCID: PMC8051801.
      Citations: 1     Fields:    Translation:Humans
    37. Alhalabi O, Soomro Z, Sun R, Hasanov E, Albittar A, Tripathy D, Valero V, Ibrahim NK. Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. NPJ Breast Cancer. 2021 Mar 19; 7(1):28. PMID: 33742001; PMCID: PMC7979865.
      Citations:    
    38. Partain N, Postlewait LM, Teshome M, Rosso K, Hall C, Song J, Meas S, DeSnyder SM, Lim B, Valero V, Woodward W, Ueno NT, Kuerer H, Lucci A. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Aug; 28(8):4265-4274. PMID: 33403525.
      Citations: 4     Fields:    Translation:Humans
    39. Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist. 2021 02; 26(2):e230-e240. PMID: 33140515; PMCID: PMC7873313.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    40. Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel). 2020 Oct 24; 12(11). PMID: 33114311; PMCID: PMC7690918.
      Citations:    
    41. Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12. PMID: 32920733; PMCID: PMC8294182.
      Citations: 2     Fields:    Translation:Humans
    42. Chainitikun S, Saleem S, Lim B, Valero V, Ueno NT. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res. 2021 03; 29:1-12. PMID: 33842000; PMCID: PMC8020152.
      Citations:    Fields:    Translation:Humans
    43. Candelaria RP, Adrada BE, Hess K, Santiago L, Lane DL, Thompson AM, Moulder SL, Huang ML, Arribas EM, Rauch GM, Leung JWT, Symmans WF, Valero V, Ravenberg EE, White JB, Yang WT. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol. 2020 Sep; 130:109170. PMID: 32777736; PMCID: PMC7534548.
      Citations: 1     Fields:    Translation:Humans
    44. Lau R, Du L, Chen E, Fu C, Gould R, Marczyk M, Layman R, Bedrosian I, Valero V, Symmans WF, Sinn BV. Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. Clin Chem. 2020 07 01; 66(7):934-945. PMID: 32613237.
      Citations:    Fields:    Translation:Humans
    45. Le Du F, Fujii T, Kida K, Davis DW, Park M, Liu DD, Wu W, Chavez-MacGregor M, Barcenas CH, Valero V, Tripathy D, Reuben JM, Ueno NT. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream? in patients with breast cancer treated with primary systemic therapy. PLoS One. 2020; 15(3):e0229903. PMID: 32214335; PMCID: PMC7098555.
      Citations: 13     Fields:    Translation:HumansCells
    46. Murthy RK, Song J, Raghavendra AS, Li Y, Hsu L, Hess KR, Barcenas CH, Valero V, Tripathy D, Hortobagyi GN, Carlson RW. Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. NPJ Breast Cancer. 2020; 6:11. PMID: 32219153; PMCID: PMC7096449.
      Citations: 1     
    47. Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist. 2020 06; 25(6):e909-e919. PMID: 32003919; PMCID: PMC7288623.
      Citations: 1     Fields:    Translation:Humans
    48. Suarez-Pierre A, Zhou X, Fraser CD, Grimm JC, Crawford TC, Lui C, Valero V, Choi CW, Higgins RS, Kilic A. Survival and Functional Status After Bridge-to-Transplant with a Left Ventricular Assist Device. ASAIO J. 2019 Sep/Oct; 65(7):661-667. PMID: 30281540.
      Citations: 6     Fields:    Translation:Humans
    49. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394. PMID: 31461380; PMCID: PMC7351336.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    50. Sun S, van la Parra RFD, Rauch GM, Checka C, Tadros AB, Lucci A, Teshome M, Black D, Hwang RF, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079. PMID: 31342361.
      Citations: 4     Fields:    Translation:Humans
    51. Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78. PMID: 31277699; PMCID: PMC6612080.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    52. Seykora TF, Ecker BL, McMillan MT, Maggino L, Beane JD, Fong ZV, Hollis RH, Jamieson NB, Javed AA, Kowalsky SJ, Kunstman JW, Malleo G, Poruk KE, Soares K, Valero V, Velu LKP, Watkins AA, Vollmer CM, Pancreas Fistula Study Group. The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. Ann Surg. 2019 07; 270(1):147-157. PMID: 29489483.
      Citations: 10     Fields:    Translation:Humans
    53. Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112. PMID: 31097774; PMCID: PMC6738035.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    54. Cohen EN, Fouad TM, Lee BN, Arun BK, Liu D, Tin S, Gutierrez Barrera AM, Miura T, Kiyokawa I, Yamashita J, Alvarez RH, Valero V, Woodward WA, Shen Y, Ueno NT, Cristofanilli M, Reuben JM. Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Res Treat. 2019 Aug; 176(3):545-556. PMID: 31054033; PMCID: PMC6653624.
      Citations: 5     Fields:    Translation:Humans
    55. Baez-Vallecillo L, Raghavendra AS, Hess KR, Barcenas CH, Moulder SL, Tripathy D, Valero V, Murthy RK. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019 Jul; 176(1):227-234. PMID: 30977027.
      Citations: 6     Fields:    Translation:Humans
    56. Maggino L, Malleo G, Bassi C, Allegrini V, Beane JD, Beckman RM, Chen B, Dickson EJ, Drebin JA, Ecker BL, Fraker DL, House MG, Jamieson NB, Javed AA, Kowalsky SJ, Lee MK, McMillan MT, Roses RE, Salvia R, Valero V, Velu LKP, Wolfgang CL, Zureikat AH, Vollmer CM. Identification of an Optimal Cut-off for Drain Fluid Amylase on Postoperative Day 1 for Predicting Clinically Relevant Fistula After Distal Pancreatectomy: A Multi-institutional Analysis and External Validation. Ann Surg. 2019 02; 269(2):337-343. PMID: 28938266.
      Citations: 12     Fields:    Translation:Humans
    57. Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351. PMID: 30610588.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    58. Ecker BL, McMillan MT, Allegrini V, Bassi C, Beane JD, Beckman RM, Behrman SW, Dickson EJ, Callery MP, Christein JD, Drebin JA, Hollis RH, House MG, Jamieson NB, Javed AA, Kent TS, Kluger MD, Kowalsky SJ, Maggino L, Malleo G, Valero V, Velu LKP, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM. Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy: Analysis of 2026 Resections From the International, Multi-institutional Distal Pancreatectomy Study Group. Ann Surg. 2019 01; 269(1):143-149. PMID: 28857813.
      Citations: 38     Fields:    Translation:Humans
    59. Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V. Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 12; 268(6):e61-e62. PMID: 29064904; PMCID: PMC6056325.
      Citations: 2     Fields:    Translation:Humans
    60. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109. PMID: 30311036.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    61. Fouad TM, Ueno NT, Yu RK, Ensor JE, Alvarez RH, Krishnamurthy S, Lucci A, Reuben JM, Yang W, Willey JS, Valero V, Bondy ML, Cristofinalli M, Shete S, Woodward WA, El-Zein R. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS One. 2018; 13(9):e0204372. PMID: 30248155; PMCID: PMC6152950.
      Citations: 7     Fields:    Translation:Humans
    62. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213. PMID: 29879283; PMCID: PMC6143003.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    63. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309. PMID: 30139837; PMCID: PMC6291334.
      Citations: 20     Fields:    Translation:Humans
    64. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288. PMID: 30077429.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    65. Stecklein SR, Park M, Liu DD, Valle Goffin JJ, Caudle AS, Mittendorf EA, Barcenas CH, Mougalian S, Woodward WA, Valero V, Sahin AA, Yang WT, Shaitelman SF. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):568-577. PMID: 29928946.
      Citations: 2     Fields:    Translation:Humans
    66. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951. PMID: 28549010; PMCID: PMC6051523.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    67. Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447. PMID: 29721054; PMCID: PMC5929089.
      Citations: 29     
    68. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305. PMID: 29579338.
      Citations: 6     Fields:    Translation:Humans
    69. Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs. 2018 04; 36(2):299-306. PMID: 29374384.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    70. Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WA. Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer. 2018 May; 26(5):1561-1568. PMID: 29197959.
      Citations: 3     Fields:    Translation:Humans
    71. Chaoul A, Milbury K, Spelman A, Basen-Engquist K, Hall MH, Wei Q, Shih YT, Arun B, Valero V, Perkins GH, Babiera GV, Wangyal T, Engle R, Harrison CA, Li Y, Cohen L. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer. 2018 Jan 01; 124(1):36-45. PMID: 28940301; PMCID: PMC5735004.
      Citations: 15     Fields:    Translation:Humans
    72. Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJ. Risk factors for falls in older patients with cancer. BMJ Support Palliat Care. 2018 Mar; 8(1):34-37. PMID: 28860112.
      Citations: 6     Fields:    Translation:Humans
    73. Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP, Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJ. Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. J Geriatr Oncol. 2018 01; 9(1):81-83. PMID: 28844850.
      Citations: 3     Fields:    Translation:Humans
    74. Ecker BL, McMillan MT, Maggino L, Allegrini V, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Bloomston M, Callery MP, Christein JD, Dickson E, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Salem RR, Soares KC, Valero V, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM. Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies. J Gastrointest Surg. 2018 01; 22(1):68-76. PMID: 28840459.
      Citations: 6     Fields:    
    75. Valero V, He J, Ahuja N, Cameron JL, Weiss MJ, Lennon AM, Goggins M, Wood LD, Wolfgang CL, Poruk KE. Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions. Pancreas. 2017 08; 46(7):943-947. PMID: 28697136.
      Citations: 11     Fields:    Translation:HumansCells
    76. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009. PMID: 28819400; PMCID: PMC5559961.
      Citations: 6     
    77. Shafaee MN, Salahudeen AA, Valero V. Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. J Oncol Pract. 2017 08; 13(8):555-556. PMID: 28678590.
      Citations: 1     Fields:    Translation:Humans
    78. Candelaria RP, Hansakul P, Thompson AM, Le-Petross H, Valero V, Bassett R, Huang ML, Santiago L, Adrada BE. Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated? Am J Surg. 2018 Apr; 215(4):693-698. PMID: 28712671; PMCID: PMC5748371.
      Citations: 2     Fields:    Translation:Humans
    79. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670. PMID: 28423171; PMCID: PMC5547923.
      Citations: 39     Fields:    Translation:Humans
    80. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2017 May 30; 8(22):35656-35668. PMID: 27374101; PMCID: PMC5482606.
      Citations: 21     Fields:    Translation:HumansCells
    81. Woodward WA, Fang P, Arriaga L, Gao H, Cohen EN, Reuben JM, Valero V, Le-Petross H, Middleton LP, Babiera GV, Strom EA, Tereffe W, Hoffman K, Smith BD, Buchholz TA, Perkins GH. A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):777-783. PMID: 28843370; PMCID: PMC6072264.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    82. Allegrini V, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Bloomston M, Callery MP, Christein JD, Dickson E, Dixon E, Drebin JA, Fernandez-Del Castillo C, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, McElhany AL, Salem RR, Soares KC, Sprys MH, Valero V, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM, McMillan MT. Incorporation of Procedure-specific Risk Into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality After Pancreatoduodenectomy. Ann Surg. 2017 05; 265(5):978-986. PMID: 27232260.
      Citations: 27     Fields:    Translation:Humans
    83. Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol. 2017 04; 18(4):e228-e232. PMID: 28368261; PMCID: PMC6140765.
      Citations: 43     Fields:    Translation:Humans
    84. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
    85. Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(2):263-272. PMID: 28243898.
      Citations: 15     Fields:    Translation:Humans
    86. Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer. 2017 Jul 01; 123(13):2422-2431. PMID: 28199747; PMCID: PMC5568788.
      Citations: 13     Fields:    Translation:Humans
    87. Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060. PMID: 28135148; PMCID: PMC5455352.
      Citations: 161     Fields:    Translation:Humans
    88. Valero V, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL, Poruk KE. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg. 2016 Dec; 264(6):1073-1081. PMID: 26756760; PMCID: PMC4936958.
      Citations: 65     Fields:    Translation:HumansCells
    89. Chavez-MacGregor M, Valero V, Black W, Black DM, Goravanchi F, Ifeanyi IC, Hernandez M, Rodriguez-Restrepo A, Gottumukkala V, Cata JP. The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery. Reg Anesth Pain Med. 2016 Nov/Dec; 41(6):696-703. PMID: 27685344.
      Citations: 11     Fields:    Translation:Humans
    90. Hassan SA, Yusuf SW, Sharma J, Khan J, Guindani M, Valero V, Chavez-McGregor M, Banchs J. Predictors of left ventricular systolic function recovery in the setting of sinus tachycardia in patients with cancer. Echocardiography. 2017 Jan; 34(1):29-36. PMID: 27767228.
      Citations:    Fields:    Translation:Humans
    91. Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Hatzis C, Pusztai L, Murthy R. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. J Clin Oncol. 2016 10 10; 34(29):3511-3517. PMID: 27298406; PMCID: PMC6075965.
      Citations: 29     Fields:    Translation:Humans
    92. Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. 2016 10 10; 34(29):3518-3528. PMID: 27573653; PMCID: PMC5074347.
      Citations: 35     Fields:    Translation:Humans
    93. Soi S, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, Miller BC, Salem RR, Soares K, Valero V, Wolfgang CL, Vollmer CM, McMillan MT. Risk-adjusted Outcomes of Clinically Relevant Pancreatic Fistula Following Pancreatoduodenectomy: A Model for Performance Evaluation. Ann Surg. 2016 Aug; 264(2):344-52. PMID: 26727086.
      Citations: 33     Fields:    Translation:Humans
    94. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77. PMID: 27287781; PMCID: PMC5989315.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    95. Grimm JC, Sciortino CM, Magruder JT, Dungan SP, Valero V, Sharma K, Tedford RJ, Russell SD, Whitman GJ, Silvestry SC, Shah AS. Outcomes in Patients Bridged With Univentricular and Biventricular Devices in the Modern Era of Heart Transplantation. Ann Thorac Surg. 2016 Jul; 102(1):102-8. PMID: 27068177.
      Citations: 2     Fields:    Translation:Humans
    96. Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16. PMID: 26720612; PMCID: PMC4845895.
      Citations: 41     Fields:    Translation:Humans
    97. Loveland-Jones C, Lin H, Shen Y, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno N, Valero V, Babiera G. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast?Cancer. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1218-25. PMID: 27209502; PMCID: PMC6051526.
      Citations: 2     Fields:    Translation:Humans
    98. Kronowitz SJ, Mandujano CC, Liu J, Kuerer HM, Smith B, Garvey P, Jagsi R, Hsu L, Hanson S, Valero V. Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study. Plast Reconstr Surg. 2016 Feb; 137(2):385-393. PMID: 26818270.
      Citations: 49     Fields:    Translation:Humans
    99. Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016 Mar; 27(3):359-66. PMID: 26797453; PMCID: PMC4778706.
      Citations: 15     Fields:    Translation:Humans
    100. Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, Wild AT, Shin EJ, Khashab MA, O'Broin-Lennon AM, Ali SZ, Laheru D, Hruban RH, Iacobuzio-Donahue CA, Herman JM, Wolfgang CL, Valero V. Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. Ann Surg. 2016 Jan; 263(1):153-61. PMID: 26020105; PMCID: PMC4662640.
      Citations: 19     Fields:    Translation:HumansCells
    101. Sanford RA, Lei X, Barcenas CH, Mittendorf EA, Caudle AS, Valero V, Tripathy D, Giordano SH, Chavez-MacGregor M. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Ann Surg Oncol. 2016 May; 23(5):1515-21. PMID: 26678405.
      Citations: 23     Fields:    Translation:Humans
    102. Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Valero V, Ueno NT, Hortob?gyi GN. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist. 2016 Jan; 21(1):21-7. PMID: 26659222; PMCID: PMC4709200.
      Citations: 9     Fields:    Translation:HumansCells
    103. Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2015 Dec; 1(9):1311-8. PMID: 26402167; PMCID: PMC5575939.
      Citations: 28     Fields:    Translation:Humans
    104. Grimm JC, Shah AS, Magruder JT, Kilic A, Valero V, Dungan SP, Tedford RJ, Russell SD, Whitman GJ, Sciortino CM. MELD-XI Score Predicts Early Mortality in Patients After Heart Transplantation. Ann Thorac Surg. 2015 Nov; 100(5):1737-43. PMID: 26387720.
      Citations: 12     Fields:    Translation:Humans
    105. Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, DeSnyder S, Anderson AE, Valero V, Ueno NT, Li Y, Su X, Lucci A. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst. 2015 Nov; 107(11). PMID: 26374427; PMCID: PMC4849361.
      Citations: 9     Fields:    Translation:HumansCells
    106. Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE, Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015 Dec 15; 121(24):4324-32. PMID: 26348887; PMCID: PMC4825322.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    107. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 01; 121(19):3422-7. PMID: 26280679; PMCID: PMC4829956.
      Citations: 17     Fields:    Translation:Humans
    108. Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez-MacGregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153(2):417-23. PMID: 26272743.
      Citations: 8     Fields:    Translation:Humans
    109. Grimm JC, Valero V, Magruder JT, Kilic A, Dungan SP, Silhan LL, Shah PD, Kim BS, Merlo CA, Sciortino CM, Shah AS. A novel risk score that incorporates recipient and donor variables to predict 1-year mortality in the current era of lung transplantation. J Heart Lung Transplant. 2015 Nov; 34(11):1449-54. PMID: 26275639.
      Citations: 7     Fields:    Translation:Humans
    110. McMillan MT, Vollmer CM, Asbun HJ, Ball CG, Bassi C, Beane JD, Berger AC, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, McElhany AL, Salem RR, Soares K, Sprys MH, Valero V, Watkins AA, Wolfgang CL, Behrman SW. The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy. J Gastrointest Surg. 2016 Feb; 20(2):262-76. PMID: 26162925.
      Citations: 31     Fields:    Translation:Humans
    111. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):417. PMID: 26092296.
      Citations: 1     Fields:    
    112. Hicks CW, Tosoian JJ, Craig-Schapiro R, Valero V, Cameron JL, Eckhauser FE, Hirose K, Makary MA, Pawlik TM, Ahuja N, Weiss MJ, Wolfgang CL. Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy. Am J Surg. 2015 Oct; 210(4):636-42.e1. PMID: 26384793; PMCID: PMC4634566.
      Citations: 4     Fields:    Translation:Humans
    113. Valero V, Pawlik TM, Anders RA. Emerging role of Hpo signaling and YAP in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015; 2:69-78. PMID: 27508196; PMCID: PMC4918286.
      Citations: 19     
    114. Grimm JC, Kilic A, Shah AS, Trent Magruder J, Valero V, Dungan SP, Russell SD, Tedford RJ, Whitman GJ, Sciortino CM. The influence of institutional volume on the incidence of complications and their effect on mortality after heart transplantation. J Heart Lung Transplant. 2015 Nov; 34(11):1390-7. PMID: 26296959.
      Citations:    Fields:    Translation:Humans
    115. Grimm JC, Valero V, Kilic A, Magruder JT, Merlo CA, Shah PD, Shah AS. Association Between Prolonged Graft Ischemia and Primary Graft Failure or Survival Following Lung Transplantation. JAMA Surg. 2015 Jun; 150(6):547-53. PMID: 25874575.
      Citations: 12     Fields:    Translation:Humans
    116. Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA, Tsai CJ. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol. 2015 Jun; 38(3):242-7. PMID: 23648437; PMCID: PMC3880388.
      Citations: 9     Fields:    Translation:Humans
    117. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16. PMID: 26017070; PMCID: PMC4492876.
      Citations: 30     Fields:    Translation:Humans
    118. Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol. 2015 Jul 10; 33(20):2239-45. PMID: 25987700; PMCID: PMC5098846.
      Citations: 43     Fields:    Translation:Humans
    119. Shaitelman SF, Tereffe W, Dogan BE, Hess KR, Caudle AS, Valero V, Stauder MC, Krishnamurthy S, Candelaria RP, Strom EA, Woodward WA, Hunt KK, Buchholz TA, Whitman GJ. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10. PMID: 26279028.
      Citations: 1     Fields:    Translation:Humans
    120. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer. 2015 Oct; 15(5):325-31. PMID: 25913905; PMCID: PMC4568133.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    121. Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J. 2015 May-Jun; 21(3):260-7. PMID: 25789811; PMCID: PMC5411012.
      Citations: 9     Fields:    Translation:Humans
    122. Anderson KO, Palos GR, Mendoza TR, Cleeland CS, Liao KP, Fisch MJ, Garcia-Gonzalez A, Rieber AG, Nazario LA, Valero V, Hahn KM, Person CL, Payne R. Automated pain intervention for underserved minority women with breast cancer. Cancer. 2015 Jun 01; 121(11):1882-90. PMID: 25711974; PMCID: PMC4527331.
      Citations: 11     Fields:    Translation:Humans
    123. Tosoian JJ, Hicks CW, Cameron JL, Valero V, Eckhauser FE, Hirose K, Makary MA, Pawlik TM, Ahuja N, Weiss MJ, Wolfgang CL. Tracking early readmission after pancreatectomy to index and nonindex institutions: a more accurate assessment of readmission. JAMA Surg. 2015 Feb; 150(2):152-8. PMID: 25535811; PMCID: PMC4461067.
      Citations: 12     Fields:    Translation:Humans
    124. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer. 2015; 6(4):310-8. PMID: 25767600; PMCID: PMC4349870.
      Citations: 8     
    125. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 2015 Jan 09; 17:2. PMID: 25572591; PMCID: PMC4318180.
      Citations: 19     Fields:    Translation:HumansCells
    126. Valero V, Grimm JC, Kilic A, Lewis RL, Tosoian JJ, He J, Griffin JF, Cameron JL, Weiss MJ, Vollmer CM, Wolfgang CL, Pancreas Readmission Assessment Group Study. A novel risk scoring system reliably predicts readmission after pancreatectomy. J Am Coll Surg. 2015 Apr; 220(4):701-13. PMID: 25797757; PMCID: PMC4452114.
      Citations: 7     Fields:    Translation:Humans
    127. Murthy RK, Theriault RL, Barnett CM, Hodge S, Ramirez MM, Milbourne A, Rimes SA, Hortobagyi GN, Valero V, Litton JK. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res. 2014 Dec 30; 16(6):500. PMID: 25547133; PMCID: PMC4303207.
      Citations: 15     Fields:    Translation:Humans
    128. Grimm JC, Valero V, Kilic A, Crawford TC, Conte JV, Merlo CA, Shah PD, Shah AS. Preoperative performance status impacts perioperative morbidity and mortality after lung transplantation. Ann Thorac Surg. 2015 Feb; 99(2):482-9. PMID: 25528724.
      Citations: 12     Fields:    Translation:Humans
    129. Grimm JC, Lui C, Kilic A, Valero V, Sciortino CM, Whitman GJ, Shah AS. A risk score to predict acute renal failure in adult patients after lung transplantation. Ann Thorac Surg. 2015 Jan; 99(1):251-7. PMID: 25440281.
      Citations: 12     Fields:    Translation:Humans
    130. Valero V, Amini N, Spolverato G, Weiss MJ, Hirose K, Dagher NN, Wolfgang CL, Cameron AA, Philosophe B, Kamel IR, Pawlik TM. Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg. 2015 Feb; 19(2):272-81. PMID: 25389056; PMCID: PMC4332815.
      Citations: 55     Fields:    Translation:Humans
    131. Su X, Chen Y, Zhang J, Yao H, Valero V, Weinstein JN, Meric-Bernstam F, Esteva FJ, Malouf GG, Spano JP, Khayat D. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget. 2014 Oct 30; 5(20):9864-76. PMID: 25296969; PMCID: PMC4259443.
      Citations: 106     Fields:    Translation:HumansCells
    132. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84. PMID: 25253784; PMCID: PMC4258414.
      Citations: 16     Fields:    Translation:HumansCells
    133. Kai M, Kogawa T, Liu DD, Fouad TM, Kai K, Niikura N, Hsu L, Willey JS, Theriault RL, Valero V, Ueno NT. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers. Clin Breast Cancer. 2015 Feb; 15(1):37-42. PMID: 25258308.
      Citations: 3     Fields:    Translation:Humans
    134. Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat. 2014 Aug; 146(3):477-86. PMID: 25038877.
      Citations: 22     Fields:    Translation:Humans
    135. Spolverato G, Kim Y, Ejaz A, Valero V, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Acher AW, Votanopoulos K, Schmidt C, Cho CS, Maithel SK, Pawlik TM. A multi-institutional analysis of open versus minimally-invasive surgery for gastric adenocarcinoma: results of the US gastric cancer collaborative. J Gastrointest Surg. 2014 Sep; 18(9):1563-74. PMID: 24912915.
      Citations: 7     Fields:    Translation:Humans
    136. Valero V. Carboplatin for early triple-negative breast cancer? Lancet Oncol. 2014 Jun; 15(7):676-8. PMID: 24872096.
      Citations:    Fields:    Translation:Humans
    137. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget. 2014 May 15; 5(9):2349-54. PMID: 24811890; PMCID: PMC4058010.
      Citations: 34     Fields:    Translation:Humans
    138. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8. PMID: 24721590.
      Citations: 38     Fields:    Translation:Humans
    139. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8. PMID: 24677057.
      Citations: 20     Fields:    Translation:Humans
    140. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7. PMID: 24669015; PMCID: PMC4037860.
      Citations: 49     Fields:    Translation:HumansCellsCTClinical Trials
    141. Grimm JC, Valero V, Molena D. Surgical indications and optimization of patients for resectable esophageal malignancies. J Thorac Dis. 2014 Mar; 6(3):249-57. PMID: 24624289; PMCID: PMC3949183.
      Citations: 7     
    142. Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014 Mar 10; 32(8):735-44. PMID: 24470007; PMCID: PMC3940536.
      Citations: 73     Fields:    Translation:Humans
    143. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One. 2014; 9(1):e83113. PMID: 24416156; PMCID: PMC3885405.
      Citations: 38     Fields:    Translation:HumansCells
    144. Johnston FM, Tergas AI, Bennett JL, Valero V, Morrissey CK, Fader AN, Hobson DB, Weaver SJ, Rosen MA, Wick EC. Measuring briefing and checklist compliance in surgery: a tool for quality improvement. Am J Med Qual. 2014 Nov-Dec; 29(6):491-8. PMID: 24270170.
      Citations: 4     Fields:    Translation:Humans
    145. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-Macgregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus. 2013; 2:409. PMID: 24156086; PMCID: PMC3797914.
      Citations: 8     
    146. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40. PMID: 23948975; PMCID: PMC3813597.
      Citations: 290     Fields:    Translation:Humans
    147. Eckmann K, Michaud LB, Rivera E, Madden TL, Esparza-Guerra L, Kawedia J, Booser DJ, Green MC, Hortobagyi GN, Valero V. Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. J Oncol Pharm Pract. 2014 Apr; 20(2):120-9. PMID: 23676510.
      Citations: 8     Fields:    Translation:Humans
    148. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6. PMID: 23242617; PMCID: PMC3867793.
      Citations: 9     Fields:    Translation:Humans
    149. Valero V. Managing ixabepilone adverse events with dose reduction. Clin Breast Cancer. 2013 Feb; 13(1):1-6. PMID: 23098573.
      Citations: 1     Fields:    Translation:Humans
    150. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012 Nov; 11(11):2526-34. PMID: 22973057; PMCID: PMC3500676.
      Citations: 97     Fields:    Translation:HumansCells
    151. Valero V, Cosgrove D, Herman JM, Pawlik TM. Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol. 2012 Aug; 6(4):481-95. PMID: 22928900; PMCID: PMC3538366.
      Citations: 23     Fields:    Translation:Humans
    152. Alvarez RH, Gong Y, Ueno NT, Alizadeh PA, Hortobagyi GN, Valero V. Metastasis in the breast mimicking inflammatory breast cancer. J Clin Oncol. 2012 Aug 01; 30(22):e202-6. PMID: 22734030.
      Citations: 2     Fields:    Translation:Humans
    153. Valero V, Vrdoljak E, Xu B, Thomas E, Manikhas A, Medina C, Li RK, Ro J, Bosserman L, Vahdat L, Mukhopadhyay P, Opatt D, Sparano JA, G?mez H. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer. 2012 Aug; 12(4):240-6. PMID: 22658378.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    154. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012 Aug; 12(4):264-9. PMID: 22591634.
      Citations: 46     Fields:    Translation:HumansCells
    155. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Ueno NT, Hortob?gyi GN. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012; 17(7):891-9. PMID: 22584436; PMCID: PMC3399643.
      Citations: 49     Fields:    Translation:Humans
    156. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5. PMID: 22331946.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    157. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 01; 30(7):729-34. PMID: 22291085.
      Citations: 92     Fields:    Translation:Humans
    158. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012 May; 151(5):710-6. PMID: 22285778; PMCID: PMC3628698.
      Citations: 36     Fields:    Translation:Humans
    159. Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1381-6. PMID: 22284689.
      Citations: 8     Fields:    Translation:Humans
    160. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83. PMID: 22147002; PMCID: PMC3248766.
      Citations: 42     Fields:    Translation:Humans
    161. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):276-82. PMID: 22102688.
      Citations:    Fields:    Translation:Humans
    162. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783; PMCID: PMC3233286.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    163. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol. 2012 May; 23(5):1144-1150. PMID: 21965473.
      Citations: 48     Fields:    Translation:HumansCells
    164. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012 May 01; 118(9):2385-93. PMID: 21953213; PMCID: PMC3274632.
      Citations: 21     Fields:    Translation:Humans
    165. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46. PMID: 21900106; PMCID: PMC4874218.
      Citations: 62     Fields:    Translation:Humans
    166. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec 15; 117(24):5476-84. PMID: 21713757.
      Citations: 35     Fields:    Translation:Humans
    167. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67. PMID: 21699723; PMCID: PMC3218956.
      Citations: 93     Fields:    Translation:HumansCells
    168. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34. PMID: 21606433; PMCID: PMC3139370.
      Citations: 64     Fields:    Translation:Humans
    169. Alvarez RH, Valero V, Hortobagyi GN. Ixabepilone for the treatment of breast cancer. Ann Med. 2011; 43(6):477-86. PMID: 21585248.
      Citations: 2     Fields:    Translation:Humans
    170. Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer. 2012 Jan 15; 118(2):326-32. PMID: 21590688; PMCID: PMC3158806.
      Citations: 5     Fields:    Translation:Humans
    171. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb; 125(3):785-95. PMID: 21153052; PMCID: PMC4109066.
      Citations: 32     Fields:    Translation:HumansCells
    172. Valero V, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer. 2010 Dec 01; 10(6):477-82. PMID: 21147692.
      Citations: 2     Fields:    Translation:Humans
    173. Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011 Jan 10; 29(2):149-56. PMID: 21115860.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    174. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer. 2011 Jul 15; 129(2):417-23. PMID: 20857493.
      Citations: 56     Fields:    Translation:HumansCells
    175. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer. 2010 Oct 26; 103(9):1331-4. PMID: 20877352; PMCID: PMC2990606.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    176. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010 Sep 20; 28(27):4111-9. PMID: 20697068; PMCID: PMC2953969.
      Citations: 126     Fields:    Translation:HumansCells
    177. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol. 2010 Dec; 21(12):2348-2355. PMID: 20439340.
      Citations: 12     Fields:    Translation:Humans
    178. [Third revision of the National Consensus on Diagnosis and Treatment of Breast Cancer (third of three parts)]. Ginecol Obstet Mex. 2010 Mar; 78(3):199-212. PMID: 20939226.
      Citations: 1     Fields:    Translation:Humans
    179. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9. PMID: 20008624; PMCID: PMC2815707.
      Citations: 186     Fields:    Translation:HumansCTClinical Trials
    180. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6. PMID: 19884543; PMCID: PMC2792998.
      Citations: 138     Fields:    Translation:Humans
    181. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010 Jan; 21(1):33-9. PMID: 19602564.
      Citations: 31     Fields:    Translation:HumansCells
    182. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009 May 15; 69(10):4116-24. PMID: 19435916; PMCID: PMC2737191.
      Citations: 385     Fields:    Translation:HumansCells
    183. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008 Sep 10; 26(26):4282-8. PMID: 18779615; PMCID: PMC6366335.
      Citations: 212     Fields:    Translation:Humans
    184. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83. PMID: 18695137; PMCID: PMC6592411.
      Citations: 148     Fields:    Translation:Humans
    185. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Mills GB, Hennessy BT, Bernards R. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008 Aug 01; 68(15):6084-91. PMID: 18676830; PMCID: PMC2680495.
      Citations: 498     Fields:    Translation:Humans
    186. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan; 135(1):141-8. PMID: 18581139.
      Citations: 4     Fields:    Translation:Humans
    187. Limentani S, Romieu G, Lortholary A, Kaufman P, Girre V, Besenval M, Valero V, Di?ras V, Tubiana-Hulin M. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008 Jul; 19(7):1255-1260. PMID: 18381372.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    188. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007 Mar; 8(3):203-11. PMID: 17329190.
      Citations: 73     Fields:    Translation:Humans
    189. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007 Feb; 7(6):471-9. PMID: 17386124.
      Citations: 61     Fields:    Translation:HumansCells
    190. Blancas I, Bermejo B, Hanrahan EO, Monteagudo C, Rouzier R, Hennessy BT, Valero V, Lluch A, Garc?a-Puche JL, Mart?nez-Agull? A. Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor. Ann Oncol. 2006 Nov; 17(11):1644-9. PMID: 16873428.
      Citations: 8     Fields:    Translation:Humans
    191. Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA, Babiera G, Hortobagyi GN, Valero V. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006 Apr; 17(4):605-13. PMID: 16469754.
      Citations: 79     Fields:    Translation:Humans
    192. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005 Nov 01; 23(31):7820-6. PMID: 16258084.
      Citations: 206     Fields:    Translation:Humans
    193. Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valero V, Hortobagyi GN. Squamous cell carcinoma of the breast. J Clin Oncol. 2005 Nov 01; 23(31):7827-35. PMID: 16258085.
      Citations: 63     Fields:    Translation:Humans
    194. Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacother. 2005 Aug; 6(9):1477-91. PMID: 16086636.
      Citations: 13     Fields:    Translation:HumansAnimals
    195. Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol. 2005 Aug; 16(8):1289-96. PMID: 15890665.
      Citations: 19     Fields:    Translation:Humans
    196. Chagpar A, Middleton LP, Sahin AA, Meric-Bernstam F, Kuerer HM, Feig BW, Ross MI, Ames FC, Singletary SE, Buchholz TA, Valero V, Hunt KK. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6. PMID: 15747375.
      Citations: 17     Fields:    Translation:Humans
    197. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005 Apr; 6(4):229-39. PMID: 15811618.
      Citations: 87     Fields:    Translation:Humans
    198. Montero A, Booser D, Esparza-Guerra L, Murray J, Rosales M, Hortobagyi G, Valero V. Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer. Drugs R D. 2005; 6(5):299-305. PMID: 16128600.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    199. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004 Oct 01; 101(7):1508-13. PMID: 15378497.
      Citations: 7     Fields:    Translation:Humans
    200. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93. PMID: 15136595.
      Citations: 116     Fields:    Translation:Humans
    201. Rivera E, Valero V, Francis D, Asnis AG, Schaaf LJ, Duncan B, Hortobagyi GN. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res. 2004 Mar 15; 10(6):1943-8. PMID: 15041710.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    202. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 07; 25(3):94-102. PMID: 14698135.
      Citations: 128     Fields:    Translation:HumansCTClinical Trials
    203. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003 Mar; 9(3):955-60. PMID: 12631592.
      Citations: 15     Fields:    Translation:HumansCells
    204. Valero V, Buzdar AU, McNeese M, Singletary E, Hortobagyi GN. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2002 Oct; 3 Suppl 2:S63-8. PMID: 12435294.
      Citations: 11     Fields:    Translation:Humans
    205. Valero V. Primary chemotherapy with docetaxel for the management of breast cancer. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):35-43. PMID: 12108896.
      Citations: 4     Fields:    Translation:Humans
    206. Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002 Feb; 13(2):218-21. PMID: 11885997.
      Citations: 4     Fields:    Translation:Humans
    207. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001 Dec; 182(6):601-8. PMID: 11839324.
      Citations: 18     Fields:    Translation:Humans
    208. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001 Nov 15; 92(10):2523-8. PMID: 11745185.
      Citations: 56     Fields:    Translation:Humans
    209. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82. PMID: 11745249.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    210. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20. PMID: 11693900.
      Citations: 16     Fields:    Translation:Humans
    211. Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. Semin Oncol. 2001 Aug; 28(4 Suppl 12):15-23. PMID: 11552226.
      Citations: 10     Fields:    Translation:Humans
    212. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33. PMID: 11454891.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    213. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001 May 15; 19(10):2587-95. PMID: 11352950.
      Citations: 126     Fields:    Translation:HumansCTClinical Trials
    214. Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology. 2001 May; 108(5):994-5. PMID: 11320034.
      Citations: 24     Fields:    Translation:Humans
    215. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Hortobagyi GN, Esteva FL. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001 Mar 15; 19(6):1716-22. PMID: 11251001.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    216. Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71. PMID: 11241232.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    217. Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001 Feb 01; 19(3):628-33. PMID: 11157012.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    218. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001; 6(2):133-46. PMID: 11306725.
      Citations: 31     Fields:    Translation:Humans
    219. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66. PMID: 11458813.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    220. Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201. PMID: 11147589.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    221. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 2000 Nov; 23(5):401-28. PMID: 11085347.
      Citations: 23     Fields:    Translation:Humans
    222. Anderson KO, Mendoza TR, Valero V, Richman SP, Russell C, Hurley J, DeLeon C, Washington P, Palos G, Payne R, Cleeland CS. Minority cancer patients and their providers: pain management attitudes and practice. Cancer. 2000 Apr 15; 88(8):1929-38. PMID: 10760771.
      Citations: 102     Fields:    Translation:Humans
    223. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21. PMID: 10776969.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    224. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33. PMID: 10655439.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    225. Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer. 2000 Feb; 82(3):529-34. PMID: 10682660; PMCID: PMC2363337.
      Citations: 7     Fields:    Translation:Humans
    226. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000 Jan 22; 355(9200):281-3. PMID: 10675076.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    227. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7. PMID: 10550135.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    228. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7. PMID: 10506711.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    229. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34. PMID: 10334527.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    230. Cristofanilli M, Holmes FA, Esparza L, Valero V, Buzdar AU, Neidhart JA, Hortobagyi GN. Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Res Treat. 1999 Apr; 54(3):225-33. PMID: 10445421.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    231. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11. PMID: 10370782.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    232. Valero V, Hortobagyi GN. Primary chemotherapy: a better overall therapeutic option for patients with breast cancer. Ann Oncol. 1998 Nov; 9(11):1151-4. PMID: 9862043.
      Citations:    Fields:    Translation:Humans
    233. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998 Oct; 16(10):3362-8. PMID: 9779713.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    234. Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol. 1998 Oct; 21(5):442-6. PMID: 9781596.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    235. Rosner F. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998 Sep 01; 83(5):1054-5. PMID: 9731914.
      Citations:    Fields:    Translation:Humans
    236. Walters RS, Holmes FA, Valero V, Esparza-Guerra L, Hortobagyi GN. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am J Clin Oncol. 1998 Aug; 21(4):413-5. PMID: 9708645.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    237. Benjapibal M, Kudelka AP, Vasuratna A, Edwards CL, Verschraegen CF, Valero V, Vadhan-Raj S, Kavanagh JJ. Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. Anticancer Drugs. 1998 Jul; 9(6):577-9. PMID: 9877247.
      Citations: 2     Fields:    Translation:Humans
    238. Valero V. Future direction of neoadjuvant therapy for breast cancer. Semin Oncol. 1998 Apr; 25(2 Suppl 3):36-41. PMID: 9566206.
      Citations:    Fields:    Translation:Humans
    239. Diaz-Canton EA, Valero V, Rahman Z, Rodriguez-Monge E, Frye D, Smith T, Buzdar AU, Hortobagyi GN. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol. 1998 Apr; 9(4):413-8. PMID: 9636832.
      Citations: 10     Fields:    Translation:Humans
    240. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998 Mar 01; 82(5):965-9. PMID: 9486588.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    241. Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB, Bruno R. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998 Jan; 16(1):187-96. PMID: 9440742.
      Citations: 119     Fields:    Translation:HumansCTClinical Trials
    242. Rahman Z, Champlin R, Rondon G, Frye D, Valero V, Mehra R, Hortobagyi G. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol. 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PMID: 9374100.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    243. Valero V. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol. 1997 Aug; 24(4 Suppl 13):S13-11-S13-18. PMID: 9335512.
      Citations: 7     Fields:    Translation:Humans
    244. Valero V. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology (Williston Park). 1997 Aug; 11(8 Suppl 8):34-6. PMID: 9364540.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    245. Valero V. Docetaxel and cyclophosphamide in patients with advanced solid tumors. Oncology (Williston Park). 1997 Jun; 11(6 Suppl 6):21-3. PMID: 9213323.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    246. Ayoub JP, Valero V, Hortobagyi GN. Tamoxifen-induced female androgenetic alopecia in a patient with breast cancer. Ann Intern Med. 1997 May 01; 126(9):745-6. PMID: 9139575.
      Citations: 4     Fields:    Translation:Humans
    247. Hoff PM, Valero V, Holmes FA, Whealin H, Hudis C, Hortobagyi GN. Paclitaxel-induced pancreatitis: a case report. J Natl Cancer Inst. 1997 Jan 01; 89(1):91-3. PMID: 8978416.
      Citations: 4     Fields:    Translation:Humans
    248. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21. PMID: 8874332.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    249. Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, Trancik RJ, Bandstra BA, Compton LD. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996 Jul; 35(1):74-8. PMID: 8682968.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    250. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec; 13(12):2886-94. PMID: 8523051.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    251. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V, et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res. 1995 Jul 15; 55(14):3060-7. PMID: 7606728.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    252. Ravdin PM, Valero V. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol. 1995 Apr; 22(2 Suppl 4):17-21. PMID: 7740326.
      Citations: 4     Fields:    Translation:Humans
    253. Dhingra K, Valero V, Gutierrez L, Theriault R, Booser D, Holmes F, Buzdar A, Fraschini G, Hortobagyi G. Phase II study of deoxyspergualin in metastatic breast cancer. Invest New Drugs. 1994; 12(3):235-41. PMID: 7896543.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    254. Buzdar AU, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, et al. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol. 1994 Jan; 12(1):50-4. PMID: 8270984.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    255. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9. PMID: 7912522.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    256. Rodriguez RE, Valero V, Watanakunakorn C. Salmonella focal intracranial infections: review of the world literature (1884-1984) and report of an unusual case. Rev Infect Dis. 1986 Jan-Feb; 8(1):31-41. PMID: 3513285.
      Citations: 23     Fields:    Translation:HumansCells
    257. Valero V. Mesenteric laceration complicating a Heimlich maneuver. Ann Emerg Med. 1986 Jan; 15(1):105-6. PMID: 3942345.
      Citations: 5     Fields:    Translation:Humans
    258. Valero V, Senior J, Watanakunakorn C. Liver abscess complicating Crohn's disease presenting as thoracic empyema. Case report and review of the literature. Am J Med. 1985 Nov; 79(5):659-62. PMID: 4061480.
      Citations: 3     Fields:    Translation:Humans
    259. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Women's Oncology Review. 4:211-212.
    260. Genotype-phenotype correlations by ethnicity and mutation location in brca mutation carriers. Breast Journal. 21:260-267.
    261. Second-line chemotherapy for metastatic breast cancer including quality of life issues. Breast. 5:312-317.
    262. Clinical aspect of inflammatory breast cancer. 11-19.
    263. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.
    264. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Research. 17.
    265. T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with Trastuzumab and Pertuzumab. Journal of Clinical Oncology. 34:3511-3517.
    266. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thrombosis and Haemostasis. 113:593-598.
    267. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes and Control. 27:359-366.
    268. Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer. Journal of Cancer. 6:310-318.
    269. Locally advanced breast cancer. Oncologist. 1:8-17.
    270. Erratum. Breast Cancer Research and Treatment. 152:417.
    271. Cardiotoxicity of anthracycline-taxane combinations in metastatic breast cancer. Breast Diseases. 16:315-320.
    272. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment.
    273. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 1-8.
    274. Decrease in bcl-2 expression shortly after neoadjuvant chemotherapy predicts primary breast cancer response to treatment. Breast Cancer Research and Treatment. 69:244.
    275. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience. 3:164-172.
    276. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of Oncology. 21:33-39.
    277. Neoadjuvant therapy of breast cancer. American Journal of Cancer. 5:411-425.
    278. Predictors of left ventricular systolic function recovery in the setting of sinus tachycardia in patients with cancer. Echocardiography. 34:29-36.
    279. High her2/centromeric probeforchromosome17fluorescence insitu hybridization ratio predicts pathologic complete response and survival outcomein patients receiving neoadjuvant systemic therapy with trastuzumab for her2-overexpressing locally advanced breast cancer. Oncologist. 21:21-27.
    280. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Molecular Oncology. 9:32-43.
    281. Carcinosarcoma of the Breast. 257-269.
    282. Inflammatory breast cancer. PLoS One. 11.
    283. Phase I-II study to evaluate safety and efficacy of capecitabine (Xeloda) and exisulind (Aptosyn) combination therapy in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 69:285.
    284. Carcinosarcoma of the Breast. 218-229.
    285. Trastuzumab in primary inflammatory breast cancer (IBC). Breast Journal. 16:529-532.
    286. Breast cancer in identical twins with different clinical course. Breast Journal. 2:400-402.
    287. Long-term clinical outcome of patients with stage IIIc locally advanced breast cancer. Breast Diseases. 15:17-18.
    288. P53 alterations show significant correlation with gene amplification and high S-phase index in breast cancer. International Journal of Oncology. 6:955-962.
    289. The Impact of Paravertebral Block Analgesia on Breast Cancer Survival after Surgery. Regional Anesthesia and Pain Medicine. 41:696-703.
    290. Systemic and targeted therapy. 85-99.
    291. Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer. Journal of Cancer. 7:1095-1104.
    292. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology. 11:38-40.
    293. Stability of estrogen receptor status in breast carcinoma. Breast Diseases. 22:270-271.
    294. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer.
    295. HER2 gene amplification testing by fluorescent in situ hybridization (FISH). Journal of Clinical Oncology. 34:3518-3528.
    296. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 7:76362-76373.
    297. Inflammatory breast cancer. Breast Journal. 2:345-352.
    298. Molecular profiling using breast cancer subtype to plan for breast reconstruction. Plastic and Reconstructive Surgery.
    299. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics.
    300. Cáncer de mama localmente avanzado. Revisiones en Cancer. 16:295-303.
    301. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Annals of Surgical Oncology. 1-7.
    302. Phase II Randomized Study of Ixabepilone Versus Observation in Patients with Significant Residual Disease after Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer. 15:325-331.
    303. Effects of multidisciplinary team working on breast cancer survival. Breast Diseases. 23:324-325.
    304. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. Breast Diseases. 24:143-144.
    VALERO's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (595)
    Explore
    _
    Co-Authors (187)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _